Bivalirudin Pharmacokinetics

Half-Life and Clearance

• The American College of Chest Physicians recommends that bivalirudin has a plasma half-life of 25 minutes after intravenous injection in patients with normal renal function 1, 2
• The elimination half-life is approximately 25 minutes in patients undergoing percutaneous coronary intervention (PCI) with normal renal function 1, 2
• Some guidelines cite a range of 25-36 minutes for the half-life, according to the British Journal of Anaesthesia 3, 4
• The onset of anticoagulant action is rapid at 2-4 minutes, as stated by the Anaesthesia journal 5, 6, 7, 8

Renal Impairment Considerations

• The half-life is significantly prolonged in patients with renal dysfunction, requiring dose adjustments, as noted by the Anaesthesia journal 5, 6, 7, 8

Clearance Mechanism

• Bivalirudin undergoes predominantly non-renal elimination through proteolytic cleavage (80% enzymatic metabolism), according to the Anaesthesia journal 5, 6, 7, 8, 9
• Only 20% is excreted unchanged via the kidneys through glomerular filtration, as stated by the Chest journal 1, 2

Clinical Implications

• The short half-life means bivalirudin provides little to no antithrombin activity 2 hours after discontinuation, which has been associated with increased acute stent thrombosis risk in some studies, as reported by the Circulation journal 10
• Dose adjustments are required for patients with moderate to severe renal impairment but not for hepatic impairment, as recommended by the Anaesthesia journal 5, 6, 7, 8